Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioAtla (BCAB) Cash & Equivalents (2020 - 2025)

BioAtla's Cash & Equivalents history spans 6 years, with the latest figure at $4.3 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 88.92% year-over-year to $4.3 million; the TTM value through Dec 2025 reached $4.3 million, down 88.92%, while the annual FY2025 figure was $4.3 million, 88.92% down from the prior year.
  • Cash & Equivalents reached $4.3 million in Q4 2025 per BCAB's latest filing, down from $8.3 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $269.9 million in Q3 2021 to a low of $4.3 million in Q4 2025.
  • Average Cash & Equivalents over 5 years is $130.6 million, with a median of $155.0 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: soared 112730.98% in 2021, then plummeted 88.92% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $245.0 million in 2021, then dropped by 12.03% to $215.5 million in 2022, then crashed by 76.61% to $50.4 million in 2023, then decreased by 23.02% to $38.8 million in 2024, then tumbled by 88.92% to $4.3 million in 2025.
  • Per Business Quant, the three most recent readings for BCAB's Cash & Equivalents are $4.3 million (Q4 2025), $8.3 million (Q3 2025), and $18.2 million (Q2 2025).